FORM 4

(Print or Type Pecnonces)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average burden						
nours per response	e 0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Cohen Yuval				Issuer Name and Ticker or Trading Symbol Corbus Pharmaceuticals Holdings, Inc. [CRBP]						_X_ Direc	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director X_ Officer (give title below) Other (specify below) Chief Executive Officer					
(Last) (First) (Middle) C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE				3. Date of Earliest Transaction (Month/Day/Year) 11/22/2016							Cinic	Executive	, incor			
NORWOOD, MA 02062				4. If Amendment, Date Original Filed(Month/Day/Year) 11/23/2016						_X_ Form fil	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person _Form filed by More than One Reporting Person					
(City		(State)	(Zip)		Ta	ıble I	- Non	-Der	ivative :	Securitie	s Aco	uired, Disp	osed of, or l	Beneficially	Owned	
1.Title of Security 2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if		Code (Instr. 8)		1		quired of (E	d 5. Amour Beneficia	nt of Securities lly Owned Following Transaction(s)		6. Ownership Form:	7. Nature of Indirect Beneficial Ownership			
	(Month Day Tear)			ode	V	Amour	(A) or (D)	Pric		or (I)			(Instr. 4)			
Common	Common Stock 11/22/2016					P		1,340	A	\$ 7.64	4 32,830	<u>(1)</u>		D		
				Derivative Se			quire	cont the f	ained i orm dis	n this fo splays a of, or Be	orm a curi	•	uired to res OMB con	spond unle	ss	1474 (9-02)
1. Title of Derivative Security (Instr. 3)	Conversion Date Exe or Exercise (Month/Day/Year) any		3A. Deemed Execution Day Year)	4. Transaction Code Year) (Instr. 8)		5. 6 Number a		6. Da	ions, convertible securi 6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Aı Uı Se	Title and mount of inderlying ecurities instr. 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form of Derivat Security Direct (or Indir	Beneficia Ownershi (Instr. 4)
				Code	V	(A)	(D)	Date Exer	cisable	Expiration Date	on Ti	Amount or Number of Shares				

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Cohen Yuval C/O CORBUS PHARMACEUTICALS HOLDINGS, INC 100 RIVER RIDGE DRIVE NORWOOD, MA 02062	X		Chief Executive Officer			

Signatures

/s/Yuval Cohen	01/20/2017
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This amendment is being filed solely for the purpose of correcting the number of securities reported in Box 5 to Table 1 to indicate the number of securities beneficially owned following the transaction.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.